The Manufacturers Life Insurance Company Invests $333,000 in Tyra Biosciences, Inc. (NASDAQ:TYRA)

The Manufacturers Life Insurance Company acquired a new position in Tyra Biosciences, Inc. (NASDAQ:TYRA) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 14,184 shares of the company’s stock, valued at approximately $333,000.

Other hedge funds also recently made changes to their positions in the company. American Century Companies Inc. grew its stake in shares of Tyra Biosciences by 582.9% in the 2nd quarter. American Century Companies Inc. now owns 170,283 shares of the company’s stock worth $2,723,000 after purchasing an additional 145,346 shares during the last quarter. Perceptive Advisors LLC boosted its holdings in shares of Tyra Biosciences by 50.5% during the second quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock worth $16,108,000 after purchasing an additional 338,208 shares during the period. Ensign Peak Advisors Inc acquired a new stake in Tyra Biosciences in the second quarter valued at approximately $3,047,000. SG Americas Securities LLC acquired a new stake in Tyra Biosciences in the third quarter valued at approximately $311,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in Tyra Biosciences by 2.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 173,737 shares of the company’s stock valued at $4,085,000 after acquiring an additional 3,792 shares during the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Bank of America raised shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $22.00 to $31.00 in a research report on Friday, October 18th. Oppenheimer boosted their target price on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research note on Thursday, September 19th. Wedbush reiterated an “outperform” rating and set a $28.00 price target on shares of Tyra Biosciences in a research report on Friday, October 25th. Finally, HC Wainwright reduced their price target on shares of Tyra Biosciences from $32.00 to $30.00 and set a “buy” rating on the stock in a research report on Monday, November 11th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tyra Biosciences has an average rating of “Buy” and a consensus target price of $31.00.

Insider Activity

In other news, CFO Alan Fuhrman acquired 9,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average cost of $16.00 per share, with a total value of $152,000.00. Following the acquisition, the chief financial officer now owns 12,849 shares in the company, valued at approximately $205,584. This represents a 283.67 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Todd Harris sold 5,698 shares of the firm’s stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $24.31, for a total value of $138,518.38. Following the transaction, the chief executive officer now directly owns 1,496,729 shares in the company, valued at approximately $36,385,481.99. This represents a 0.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 101,050 shares of company stock valued at $2,235,492 in the last 90 days. Insiders own 15.40% of the company’s stock.

Tyra Biosciences Trading Down 1.5 %

Shares of TYRA stock opened at $14.94 on Monday. The business’s 50-day moving average price is $18.61 and its 200-day moving average price is $19.67. The firm has a market capitalization of $755.96 million, a price-to-earnings ratio of -9.28 and a beta of 1.01. Tyra Biosciences, Inc. has a 12 month low of $11.24 and a 12 month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last issued its earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). On average, sell-side analysts predict that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.